The DOI matches its Crossref record; 47 of the 51 references it cites were found in a registry or an index.
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Open accessAbstract
Glioblastoma multiforme (GBM) is the most common and lethal type of brain cancer. To identify the genetic alterations in GBMs, we sequenced 20,661 protein coding genes, determined the presence of amplifications and deletions using high-density oligonucleotide arrays, and performed gene expression analyses using next-generation sequencing technologies in 22 human tumor samples. This comprehensive analysis led to the discovery of a variety of genes that were not known to be altered in GBMs. Most notably, we found recurrent mutations in the active site of isocitrate dehydrogenase 1 ( IDH1 ) in 12% of GBM patients. Mutations in IDH1 occurred in a large fraction of young patients and in most patients with secondary GBMs and were associated with an increase in overall survival. These studies demonstrate the value of unbiased genomic analyses in the characterization of human brain cancer and identify a potentially useful genetic alteration for the classification and targeted therapy of GBMs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Gain-of-function IDH mutations are initiating events that define major clinical and prognostic classes of gliomas1,2.”
From Insulator dysfunction and oncogene activation in IDH mutant gliomas (2016) · cites this paper as [1]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Genetic and molecular markers of malignant tumors have been integrated into clinical practice 5,6 , with the US Food and Drug Administration (FDA) providing approval for several companion diagnostic devices and nucleic acid-based tests 7,8 .”
From Multimodal biomedical AI (2022) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“PI3K signaling is hyperactivated in nearly 90% of GBMs, commonly as a consequence of EGFR amplification and activating mutation (EGFRvIII), and loss of the PTEN tumor suppressor protein, a negative regulator of PI3K signaling (6–8).”
From An LXR Agonist Promotes Glioblastoma Cell Death through Inhibition of an EGFR/AKT/SREBP-1/LDLR–Dependent Pathway (2011) · cites this paper as [7]
Experimental — accuracy not yet measuredIn the citing paper
“The IDH genes (IDH1 and IDH2) encode isocitrate dehydrogenases, and mutations in these genes are among the most frequent found in diffuse gliomas118,119.”
From Transcription factors as readers and effectors of DNA methylation (2016) · cites this paper as [118]
In the citing paper
“Moreover, in the context of DNA damage, MDM2 localizes to the nucleus and modulates DNA repair in a p53-independent manner by binding to and inactivating Nbs1 in the MRE11/Rad50/NBS1 complex.1,8,27”
From Combination therapy in a xenograft model of glioblastoma: Enhancement of the antitumor activity of temozolomide by an MDM2 antagonist (2017) · cites this paper as [27]
In the citing paper
“Cancer genome sequencing efforts yielded an unexpected discovery in 2008 with the identification of somatic mutations in a metabolic enzyme, the TCA cycle enzyme IDH1, in glioblastoma multiforme (GBM) (77).”
From Fueling Immunity: Insights into Metabolism and Lymphocyte Function (2013) · cites this paper as [77]
In the citing paper
“Genomic sequencing of gliomas (Parsons et al., 2008; Yan et al., 2009) and acute myelogenous leukemia (Mardis et al., 2009) identified mutations in two isoforms of NADP+-dependent isocitrate dehydrogenase (IDH1 and IDH2).”
From Cellular Metabolism and Disease: What Do Metabolic Outliers Teach Us? (2012) · cites this paper as Parsons et al., 2008
In the citing paper
“the presence of IDH1/2 mutations in gliomas is associated with both lower histological grade and a slower rate of disease progression”
From Cellular Metabolism and Disease: What Do Metabolic Outliers Teach Us? (2012) · cites this paper as Parsons et al., 2008
In the citing paper
“the concentrations at which it accumulates under pathogenic conditions suggests HIF-1α stabilisation and impaired collagen biogenesis may contribute to tumorigenicity126-130.”
From Coupling Krebs cycle metabolites to signalling in immunity and cancer (2018) · cites this paper as [130]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
UCSF Chimera—A visualization system for exploratory research and analysis
Pettersen, E. F., Goddard, T. D., Huang, C. C., Couch, G. S., Greenblatt, D. M., Meng, E. C., & Ferrin, T. E. (2004) · Journal of Computational Chemistry · doi:10.1002/jcc.20084 · Cited by 45,882
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
The 2007 WHO Classification of Tumours of the Central Nervous System
Louis, D. N., Ohgaki, H., Wiestler, O. D., Cavenee, W. K., Burger, P. C., Jouvet, A., Scheithauer, B. W., & Kleihues, P. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0243-4 · Cited by 15,656
Mapping and quantifying mammalian transcriptomes by RNA-Seq
Mortazavi, A., Williams, B. A., McCue, K., Schaeffer, L., & Wold, B. (2008) · Nature Methods · doi:10.1038/nmeth.1226 · Cited by 13,696
SIFT: predicting amino acid changes that affect protein function
Ng, P. C. (2003) · Nucleic Acids Research · doi:10.1093/nar/gkg509 · Cited by 6,601
Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S. I., Puc, J., Miliaresis, C., Rodgers, L., McCombie, R., et al. (1997) · Science · doi:10.1126/science.275.5308.1943 · Cited by 4,785
Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses
Jones, S., Zhang, X., Parsons, D. W., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Kamiyama, H., Jimeno, A., et al. (2008) · Science · doi:10.1126/science.1164368 · Cited by 3,969
Self-citationSerial Analysis of Gene Expression
Velculescu, V. E., Zhang, L., Vogelstein, B., & Kinzler, K. W. (1995) · Science · doi:10.1126/science.270.5235.484 · Cited by 3,713
Self-citationHigh Frequency of Mutations of the PIK3CA Gene in Human Cancers
Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., Yan, H., Gazdar, A. F., Powell, S. M., Riggins, G. J., et al. (2004) · Science · doi:10.1126/science.1096502 · Cited by 3,448
Self-citationThe Consensus Coding Sequences of Human Breast and Colorectal Cancers
Sjöblom, T., Jones, S., Wood, L. D., Parsons, D. W., Lin, J., Barber, T. D., Mandelker, D. L., Leary, R. J., Ptak, J., Silliman, N., et al. (2006) · Science · doi:10.1126/science.1133427 · Cited by 3,161
Self-citation
Flagged first, then by citations
4 of the 51 references couldn’t be matched to a known paper.
Research works printed but not linked: 7
- H. Scherer, Am. J. Cancer40, 159 (1940).
- R. J. Learyet al. Proc. Natl. Acad. Sci. U.S.A. in press.
- K. Uekiet al., Cancer Res.56, 150 (1996).
- L. Frederick, X. Y. Wang, G. Eley, C. D. James, Cancer Res.60, 1383 (2000).
- G. Thielet al., Anticancer Res.15, 2495 (1995).
- S. Ekins, Y. Nikolsky, A. Bugrim, E. Kirillov, T. Nikolskaya, Methods Mol. Biol.356, 319 (2007).
- Contact information for the authors who directed the major components of this project is as follows: H. Yan G. J. Riggins (clinical and sample coordination) yan00002@mc.duke.edu griggin1@jhmi.edu; D. D. Bigner (pathological and clinical review) bigne001@mc.duke. edu; R. Karchin (bioinformatic analysis) karchin@jhu.edu; N. Papadopoulos (gene expression analysis) npapado1@jhmi.edu; G. Parmigiani (statistical analysis) gp@jhu.edu; B. Vogelstein V. E. Velculescu K. W. Kinzler (sequencing and copy number analysis) bertvog@gmail.com velculescu@jhmi.edu kinzlke@jhmi.edu. We thank N. Silliman J. Ptak L. Dobbyn and M. Whalen for assistance with PCR amplification; D. Lister L. J. Ehinger D. L. Satterfield J. D. Funkhouser and P. Killela for assistance with DNA purification; T. Sjöblom for assistance with database management; the Agencourt sequencing team for assistance with automated sequencing; and C.-S. Liu and the SoftGenetics team for their assistance with mutation detection analyses. This project was carried out under the auspices of the Ludwig Brain Tumor Initiative and was supported by the Virginia and D. K. Ludwig Fund for Cancer Research NIH grants CA121113 NS052507 CA43460 CA57345 CA62924 CA09547 5P50-NS-20023 CA108786 and CA11898 the Pew Charitable Trusts the Pediatric Brain Tumor Foundation Institute the Hirschhorn Foundation Alex's Lemonade Stand Foundation the American Brain Tumor Association the American Society of Clinical Oncology the Brain Tumor Research Fund and Beckman Coulter Corporation. Under separate licensing agreements between the Johns Hopkins University and Genzyme Beckman Coulter and Exact Sciences Corporations B.V. V.E.V. and K.W.K. are entitled to a share of royalties received by the university on sales of products related to research described in this paper. These authors and the university own Genzyme and Exact Sciences stock which is subject to certain restrictions under university policy. The terms of these arrangements are managed by the Johns Hopkins University in accordance with its conflict-of-interest policies.
Cited by
Sorted by citations
Items 401–500 of 1,034
Systematic analysis of somatic mutations in phosphorylation signaling predicts novel cancer drivers
Reimand, J., & Bader, G. D. (2013) · Molecular Systems Biology · doi:10.1038/msb.2012.68 · Cited by 274
Mukherjee, B., Mcellin, B. M., Camacho, C. V., Tomimatsu, N., Sirasanagandala, S., Nannepaga, S., Hatanpaa, K. J., Mickey, B., Madden, C. J., Maher, E. A., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4853 · Cited by 281
Rheinbay, E., Suvà, M. L., Gillespie, S. M., Wakimoto, H., Patel, A. P., Shahid, M., Oksuz, O., Rabkin, S. D., Martuza, R. L., Rivera, M. N., et al. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.04.021 · Cited by 283
PLAGL2 Regulates Wnt Signaling to Impede Differentiation in Neural Stem Cells and Gliomas
Zheng, H., Ying, H., Wiedemeyer, R., Yan, H., Quayle, S. N., Ivanova, E. V., Paik, J. H., Zhang, H., Xiao, Y., Perry, S. R., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.03.020 · Cited by 273
Self-citationZuccoli, G., Marcello, N., Pisanello, A., Servadei, F., Vaccaro, S., Mukherjee, P., & Seyfried, T. N. (2010) · Nutrition & Metabolism · doi:10.1186/1743-7075-7-33 · Cited by 266
Mao, H., LeBrun, D. G., Yang, J., Zhu, V. F., & Li, M. (2012) · Cancer Investigation · doi:10.3109/07357907.2011.630050 · Cited by 277
Møller, H. G., Rasmussen, A. P., Andersen, H. H., Johnsen, K. B., Henriksen, M., & Duroux, M. C. (2012) · Molecular Neurobiology · doi:10.1007/s12035-012-8349-7 · Cited by 273
Nürnberg, A., Kitzing, T. M., & Grosse, R. (2011) · Nature reviews. Cancer · doi:10.1038/nrc3003 · Cited by 293
Griffiths, B. L., Lewis, C. A., Bensaad, K., R�os, S., Zhang, Q., Ferber, E. C., Konisti, S., Peck, B., Miess, H., East, P., et al. (2013) · Cancer & Metabolism · doi:10.1186/2049-3002-1-3 · Cited by 271
Cell of Origin for Malignant Gliomas and Its Implication in Therapeutic DevelopmentPreprint
Zong, H., Parada, L. F., & Baker, S. J. (2015) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a020610 · Cited by 281
Liu, Y., Tao, S., Liao, L., Li, Y., Li, H., Li, Z., Lin, L., Wan, X., Yang, X., & Chen, L. (2020) · Nature Communications · doi:10.1038/s41467-019-14190-2 · Cited by 265
Does the Immune System Naturally Protect Against Cancer?
Corthay, A. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00197 · Cited by 273
Survival Outcomes and Prognostic Factors in Glioblastoma
Brown, N. F., Ottaviani, D., Tazare, J., Gregson, J., Kitchen, N. D., Brandner, S., Fersht, N. L., & Mulholland, P. J. (2022) · Cancers · doi:10.3390/cancers14133161 · Cited by 276
Using the molecular classification of glioblastoma to inform personalized treatment
Olar, A., & Aldape, K. (2013) · The Journal of Pathology · doi:10.1002/path.4282 · Cited by 278
Multimodal MRI features predict isocitrate dehydrogenase genotype in high-grade gliomas
Zhang, B., Chang, K., Ramkissoon, S. H., Tanguturi, S. K., Bi, W. L., Reardon, D. A., Ligon, K. L., Alexander, B. M., Wen, P. Y., & Huang, R. Y. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now121 · Cited by 262
Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90
Moulick, K., Ahn, J. H., Zong, H., Rodina, A., Cerchietti, L. C. A., Gomes-DaGama, E. M., Caldas-Lopes, E., Beebe, K. E., Perna, F., Hatzi, K., et al. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.670 · Cited by 261
Killela, P. J., Pirozzi, C. J., Healy, P. N., Reitman, Z. J., Lipp, E., Rasheed, B. A., Yang, R. R., Diplas, B. H., Wang, Z., Greer, P. K., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.1765 · Cited by 270
Self-citationKumar, A., White, T. A., MacKenzie, A. P., Clegg, N. J., Lee, C., Dumpit, R. F., Coleman, I. M., Ng, S. B. H., Salipante, S. J., Rieder, M. J., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1108745108 · Cited by 260
Intraoperative mass spectrometry mapping of an onco-metabolite to guide brain tumor surgery
Santagata, S., Eberlin, L. S., Norton, I. H., Calligaris, D., Feldman, D. R., Ide, J. L., Liu, X., Wiley, J. S., Vestal, M. L., Ramkissoon, S. H., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1404724111 · Cited by 264
Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics
Akinleye, A., Avvaru, P., Furqan, M., Song, Y., & Liu, D. (2013) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-6-88 · Cited by 260
Exploiting cancer cell vulnerabilities to develop a combination therapy for ras-driven tumors
De Raedt, T., Walton, Z., Yecies, J. L., Li, D., Chen, Y., Malone, C. F., Maertens, O., Jeong, S. M., Bronson, R. T., Lebleu, V., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.08.014 · Cited by 258
Agrawal, N., Jiao, Y., Sausen, M., Leary, R. J., Bettegowda, C., Roberts, N. J., Bhan, S., Ho, A. S., Khan, Z. H., Bishop, J. A., et al. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2703 · Cited by 258
Self-citationTaulli, R., Bersani, F., Foglizzo, V., Linari, A., Vigna, E., Ladanyi, M., Tuschl, T., & Ponzetto, C. (2009) · Journal of Clinical Investigation · doi:10.1172/jci38075 · Cited by 260
Targeting adaptive glioblastoma: an overview of proliferation and invasion
Xie, Q. R., Mittal, S., & Berens, M. E. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou147 · Cited by 270
Elucidating Distinct Roles for NF1 in Melanomagenesis
Maertens, O., Johnson, B., Hollstein, P., Frederick, D. T., Cooper, Z. A., Messiaen, L., Bronson, R. T., McMahon, M., Granter, S., Flaherty, K., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0313 · Cited by 258
Núñez, F. J., Mendez, F., Kadiyala, P., Alghamri, M. S., Savelieff, M. G., Garcia-Fabiani, M. B., Haase, S., Koschmann, C. J., Calinescu, A., Kamran, N., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aaq1427 · Cited by 264
NCCN Task Force Report: Evaluating the Clinical Utility of Tumor Markers in Oncology
Febbo, P. G., Ladanyi, M., Aldape, K., Marzo, A. M. D., Hammond, M. E. H., Hayes, D. F., Iafrate, A. J., Kelley, R. K., Marcucci, G., Ogino, S., et al. (2011) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2011.0137 · Cited by 262
Sos, M. L., Fischer, S., Ullrich, R. T., Peifer, M., Heuckmann, J. M., Koker, M., Heynck, S., Stückrath, I., Weiss, J. M., Fischer, F., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0907325106 · Cited by 258
DNA Methylation, Isocitrate Dehydrogenase Mutation, and Survival in Glioma
Christensen, B. C., Smith, A. A., Zheng, S., Koestler, D. C., Houseman, E. A., Marsit, C. J., Wiemels, J. L., Nelson, H. H., Karagas, M. R., Wrensch, M., et al. (2010) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djq497 · Cited by 261
Choi, Y. S., Bae, S., Chang, J. H., Kang, S., Kim, S. H., Kim, J., Rim, T. H., Choi, S. H., Jain, R., & Lee, S. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa177 · Cited by 255
Cancer biomarkers: selecting the right drug for the right patient
Kelloff, G. J., & Sigman, C. C. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3651 · Cited by 256
TET proteins and the control of cytosine demethylation in cancer
Scourzic, L., Mouly, E., & Bernard, O. (2015) · Genome Medicine · doi:10.1186/s13073-015-0134-6 · Cited by 263
Miller, J. J., Castro, L. N. G., McBrayer, S. K., Weller, M., Cloughesy, T. F., Portnow, J., Andronesi, O. C., Barnholtz‐Sloan, J. S., Baumert, B. G., Berger, M. S., et al. (2022) · Neuro-Oncology · doi:10.1093/neuonc/noac207 · Cited by 265
Self-citationWang, Y., Yang, J., Zheng, H., Tomasek, G. J., Zhang, P., McKeever, P. E., Lee, E. Y.-H. P., & Zhu, Y. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.04.001 · Cited by 256
Schiffman, J. D., Hodgson, J. G., VandenBerg, S. R., Flaherty, P., Polley, M. C., Yu, M., Fisher, P. G., Rowitch, D. H., Ford, J. M., Berger, M. S., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1851 · Cited by 254
Mutational Heterogeneity in Human Cancers: Origin and Consequences
Salk, J. J., Fox, E., & Loeb, L. A. (2009) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-121808-102113 · Cited by 266
Defects in mitochondrial metabolism and cancer
Gaude, E., & Frezza, C. (2014) · Cancer & Metabolism · doi:10.1186/2049-3002-2-10 · Cited by 266
Molecular Heterogeneity in Glioblastoma: Potential Clinical Implications
Parker, N., Khong, P., Parkinson, J., Howell, V. M., & Wheeler, H. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00055 · Cited by 263
Classification of mitocans, anti-cancer drugs acting on mitochondria
Neužil, J., Dong, L., Rohlena, J., Truksa, J., & Ralph, S. J. (2012) · Mitochondrion · doi:10.1016/j.mito.2012.07.112 · Cited by 255
DNA secondary structures and epigenetic determinants of cancer genome evolution
De, S., & Michor, F. (2011) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2089 · Cited by 253
Reproducible Quantification of Cancer-Associated Proteins in Body Fluids Using Targeted Proteomics
Hüttenhain, R., Soste, M., Selevsek, N., Röst, H. L., Sethi, A., Carapito, C., Farrah, T., Deutsch, E. W., Kusebauch, U., Moritz, R. L., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003989 · Cited by 249
Phosphoinositide 3-kinase (PI3K) pathway inhibitors in solid tumors: From laboratory to patients
Jankú, F. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.07.005 · Cited by 247
Li, F., He, X., Ye, D., Lin, Y., Yu, H., Yao, C., Huang, L., Zhang, J., Wang, F., Xu, S., et al. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.10.017 · Cited by 244
Current Therapeutic Advances Targeting EGFR and EGFRvIII in Glioblastoma
Padfield, E., Ellis, H. P., & Kurian, K. M. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00005 · Cited by 257
Mitochondrial dysfunction in neurodegenerative diseases and cancer
de Moura, M. B., Santana‐Santos, L., & Houten, B. V. (2010) · Environmental and Molecular Mutagenesis · doi:10.1002/em.20575 · Cited by 247
Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma
Kipp, B. R., Voss, J. S., Kerr, S. E., Fritcher, E. G. B., Graham, R. P., Zhang, L., Highsmith, W. E., Zhang, J., Roberts, L. R., Gores, G. J., et al. (2012) · Human Pathology · doi:10.1016/j.humpath.2011.12.007 · Cited by 243
PKM2, a Central Point of Regulation in Cancer Metabolism
Wong, N., Melo, J. D., & Tang, D. (2013) · International Journal of Cell Biology · doi:10.1155/2013/242513 · Cited by 245
Metabolism, Activity, and Targeting of D- and L-2-Hydroxyglutarates
Ye, D., Guan, K.-L., & Xiong, Y. (2018) · Trends in Cancer · doi:10.1016/j.trecan.2017.12.005 · Cited by 242
Wild-type and mutated IDH1/2 enzymes and therapy responses
Molenaar, R. J., Maciejewski, J. P., Wilmink, J. W., & Noorden, C. J. F. V. (2018) · Oncogene · doi:10.1038/s41388-017-0077-z · Cited by 249
Cancer metabolism: Key players in metabolic reprogramming
Soga, T. (2012) · Cancer Science · doi:10.1111/cas.12085 · Cited by 247
NFKBIA Deletion in Glioblastomas
Bredel, M., Scholtens, D. M., Yadav, A. K., Alvarez, A. A., Renfrow, J. J., Chandler, J. P., Yu, I. L. Y., Carro, M. S., Dai, F., Tagge, M. J., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006312 · Cited by 247
Turcan, S., Fabius, A. W. M., Borodovsky, A., Pedraza, A., Brennan, C., Huse, J., Viale, A., Riggins, G. J., & Chan, T. A. (2013) · Oncotarget · doi:10.18632/oncotarget.1412 · Cited by 240
Self-citationPaediatric and adult malignant glioma: close relatives or distant cousins?
Jones, C., Perryman, L., & Hargrave, D. R. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.87 · Cited by 249
Shi, H., Xu, J., Zhang, G., Xu, L., Li, C., Wang, L., Zhao, Z., Jiang, W., Guo, Z., & Li, X. (2013) · BMC Systems Biology · doi:10.1186/1752-0509-7-101 · Cited by 241
Targeting EGFR for Treatment of Glioblastoma: Molecular Basis to Overcome Resistance
Taylor, T. E., Furnari, F. B., & Cavenee, W. K. (2012) · Current Cancer Drug Targets · doi:10.2174/156800912799277557 · Cited by 247
Glutamine Metabolism in Cancer
Li, T., & Le, A. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-77736-8_2 · Cited by 242
Spectrum of somatic mitochondrial mutations in five cancers
Larman, T., DePalma, S. R., Hadjipanayis, A. G., Protopopov, A. I., Zhang, J., Gabriel, S., Chin, L., Seidman, C. E., Kucherlapati, R., & Seidman, J. G. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1211502109 · Cited by 240
MacLeod, G. D. A. H., Bozek, D., Rajakulendran, N., Monteiro, V., Ahmadi, M., Steinhart, Z., Kushida, M. M., Yu, H., Coutinho, F. J., Cavalli, F. M. G., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2019.03.047 · Cited by 246
Squatrito, M., Brennan, C., Helmy, K. Y., Huse, J. T., Petrini, J. H. J., & Holland, E. C. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.10.034 · Cited by 242
Heterogeneity in Cancer Metabolism: New Concepts in an Old Field
Gentric, G., Mieulet, V., & Mechta‐Grigoriou, F. (2016) · Antioxidants and Redox Signaling · doi:10.1089/ars.2016.6750 · Cited by 248
Glioblastoma Multiforme Therapy and Mechanisms of Resistance
Ramirez, Y. P., Weatherbee, J. L., Wheelhouse, R. T., & Ross, A. H. (2013) · Pharmaceuticals · doi:10.3390/ph6121475 · Cited by 243
AAV-mediated direct in vivo CRISPR screen identifies functional suppressors in glioblastoma
Chow, R. D.-W., Guzman, C. D., Wang, G., Schmidt, F., Youngblood, M. W., Ye, L., Errami, Y., Dong, M. B., Martinez, M. A. Q., Zhang, S., et al. (2017) · Nature Neuroscience · doi:10.1038/nn.4620 · Cited by 240
Novel Oncogenic PDGFRA Mutations in Pediatric High-Grade Gliomas
Paugh, B. S., Zhu, X., Qu, C., Endersby, R., Diaz, A. K., Zhang, J., Bax, D. A., Carvalho, D., Reis, R. M., Onar-Thomas, A., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1491 · Cited by 235
Rodon, J. A., Carducci, M. A., Sepúlveda-Sánchez, J. M., Azaro, A., Calvo, E., Seoane, J., Braña, I., Sicart, E., Gueorguieva, I., Cleverly, A., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1380 · Cited by 239
Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation
Wick, W., Meisner, C., Hentschel, B., Platten, M., Schilling, A., Wiestler, B., Sabel, M., Koeppen, S., Ketter, R., Weiler, M., et al. (2013) · Neurology · doi:10.1212/wnl.0b013e3182a95680 · Cited by 235
Li, J., Wang, M., Won, M., Shaw, E. G., Coughlin, C. T., Curran, W. J., & Mehta, M. P. (2010) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2010.06.012 · Cited by 233
The Glutamate Dehydrogenase Pathway and Its Roles in Cell and Tissue Biology in Health and Disease
Plaitakis, A., Kalef-Ezra, E., Kotzamani, D., Zaganas, I. V., & Spanaki, C. (2017) · Biology · doi:10.3390/biology6010011 · Cited by 252
Evading tumor evasion: Current concepts and perspectives of anti-angiogenic cancer therapy
Abdollahi, A., & Folkman, J. (2010) · Drug Resistance Updates · doi:10.1016/j.drup.2009.12.001 · Cited by 236
Molecular subclassification of diffuse gliomas: Seeing order in the chaos
Huse, J. T., PHILLIPS, H. S., & Brennan, C. (2011) · Glia · doi:10.1002/glia.21165 · Cited by 237
Mutant Isocitrate Dehydrogenase Inhibitors as Targeted Cancer Therapeutics
Golub, D., Iyengar, N. S., Dogra, S., Wong, T., Bready, D., Tang, K., Modrek, A. S., & Placantonakis, D. G. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00417 · Cited by 234
Grasso, D., Zampieri, L. X., Capelôa, T., de Velde, J. A. V., & Sonveaux, P. (2020) · Cell Stress · doi:10.15698/cst2020.06.221 · Cited by 239
An integrated genomic analysis of lung cancer reveals loss of DUSP4 in EGFR-mutant tumors
Chitale, D. A., Gong, Y., Taylor, B. S., Broderick, S., Brennan, C., Somwar, R., Golas, B., Wang, L., Motoi, N., Szőke, J., et al. (2009) · Oncogene · doi:10.1038/onc.2009.135 · Cited by 232
PIK3R1 (p85α) Is Somatically Mutated at High Frequency in Primary Endometrial Cancer
Urick, M. E., Rudd, M. L., Godwin, A. K., Sgroi, D. C., Merino, M. J., & Bell, D. W. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0549 · Cited by 236
Mcellin, B. M., Camacho, C. V., Mukherjee, B., Hahm, B., Tomimatsu, N., Bachoo, R. M., & Burma, S. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4295 · Cited by 234
2-Hydroxyglutarate Inhibits ATP Synthase and mTOR Signaling
Fu, X., Chin, R., Vergnes, L., Hwang, H., Deng, G., Xing, Y., Pai, M. Y., Li, S., Ta, L. H., Fazlollahi, F., et al. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.06.009 · Cited by 230
Shukla, N. N., Ameur, N., Yılmaz, İ., Nafa, K., Lau, C.-Y., Marchetti, A., Borsu, L. A., Barr, F. G., & Ladanyi, M. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2056 · Cited by 235
The role of neuropathology in the management of patients with diffuse low grade glioma
Cahill, D. P., Sloan, A. E., Nahed, B. V., Aldape, K., Louis, D. N., Ryken, T. C., Kalkanis, S. N., & Olson, J. J. (2015) · Journal of Neuro-Oncology · doi:10.1007/s11060-015-1909-8 · Cited by 230
Metabolic Reprogramming of Cancer Cells during Tumor Progression and Metastasis
Ohshima, K., & Morii, E. (2021) · Metabolites · doi:10.3390/metabo11010028 · Cited by 236
Heemskerk, B., Kvistborg, P., & Schumacher, T. N. (2012) · The EMBO Journal · doi:10.1038/emboj.2012.333 · Cited by 239
TET Family Proteins and Their Role in Stem Cell Differentiation and Transformation
Cimmino, L., Abdel-Wahab, O. I., Levine, R. L., & Aifantis, I. (2011) · Cell stem cell · doi:10.1016/j.stem.2011.08.007 · Cited by 237
Liu, M., Li, C., Pazgier, M., Li, C., Mao, Y., Lv, Y., Gu, B., Wei, G., Yuan, W., Zhan, C., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1008930107 · Cited by 236
The crucial role of multiomic approach in cancer research and clinically relevant outcomes
Lu, M., & Zhan, X. (2018) · The EPMA Journal · doi:10.1007/s13167-018-0128-8 · Cited by 235
Harding, J. J., Lowery, M. A., Shih, A. H., Schvartzman, J. M., Hou, S., Famulare, C. A., Patel, M. A., Roshal, M., Do, R. K. G., Zehir, A., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0877 · Cited by 238
Self-citationChang, S., Yim, S., & Park, H. (2019) · Experimental & Molecular Medicine · doi:10.1038/s12276-019-0230-6 · Cited by 228
Oligodendroglioma: pathology, molecular mechanisms and markers
Wesseling, P., van den Bent, M. J., & Perry, A. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1424-1 · Cited by 233
Clinical Implications of the Cancer Genome
MacConaill, L. E., & Garraway, L. A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.4944 · Cited by 234
Toward precision medicine in glioblastoma: the promise and the challenges
Prados, M. D., Byron, S. A., Tran, N. L., Phillips, J. J., Molinaro, A. M., Ligon, K. L., Wen, P. Y., Kuhn, J. G., Mellinghoff, I. K., de Groot, J., et al. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nov031 · Cited by 231
Acerbi, F., Broggi, M. A., Schebesch, K.-M., Höhne, J., Cavallo, C., de Laurentis, C., Eoli, M., Anghileri, E., Servida, M., Boffano, C., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1184 · Cited by 234
Combination therapy to checkmate Glioblastoma: clinical challenges and advances
Ghosh, D., Nandi, S., & Bhattacharjee, S. (2018) · Clinical and Translational Medicine · doi:10.1186/s40169-018-0211-8 · Cited by 233
Chou, W., Huang, H., Hou, H., Chen, C., Tang, J., Yao, M., Tsay, W., Ko, B., Wu, S., Huang, S., et al. (2010) · Blood · doi:10.1182/blood-2010-05-283291 · Cited by 233
Molecular and Genomic Alterations in Glioblastoma Multiforme
Crespo, I., Vital, A. L., Gonzalez-Tablas, M., Patino, M. D. C., Otero, A., Lopes, M. C., de Oliveira, C., Domingues, P., Orfao, A., & Tabernero, M. D. (2015) · The American Journal of Pathology · doi:10.1016/j.ajpath.2015.02.023 · Cited by 225
MAPK pathway activation in pilocytic astrocytoma
Jones, D., Gronych, J., Lichter, P., Witt, O., & Pfister, S. M. (2011) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-011-0898-9 · Cited by 227
Adaptive Global Innovative Learning Environment for Glioblastoma: GBM AGILE
Alexander, B. M., Ba, S., Berger, M. S., Berry, D. A., Cavenee, W. K., Chang, S. M., Cloughesy, T. F., Jiang, T., Khasraw, M., Li, W., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0764 · Cited by 229
Tian, Q., Price, N. D., & Hood, L. (2012) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2011.02498.x · Cited by 224
Cancer Cell MetabolismPreprint
Cairns, R. A., Harris, I. S., McCracken, S. A., & Mak, T. W. (2011) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2011.76.012856 · Cited by 229
Isocitrate dehydrogenase-1 mutations: A fundamentally new understanding of diffuse glioma?
Kloosterhof, N. K., Bralten, L. B., Dubbink, H. J., French, P. J., & van den Bent, M. J. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70053-x · Cited by 222
Error-prone translesion synthesis mediates acquired chemoresistance
Xie, K., Doles, J. D., Hemann, M. T., & Walker, G. C. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1011412107 · Cited by 228
Turkalp, Z. T., Karamchandani, J., & Das, S. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.1205 · Cited by 222
Hypoxia/pseudohypoxia‐mediated activation of hypoxia‐inducible factor‐1α in cancer
Hayashi, Y., Yokota, A., Harada, H., & Huang, G. (2019) · Cancer Science · doi:10.1111/cas.13990 · Cited by 229
Zdzisińska, B., Żurek, A., & Kandefer-Szerszeń, M. (2017) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-016-0406-x · Cited by 221
Metadata
- Authors
- Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., Olivi, A., McLendon, R., Rasheed, B. A., Keir, S., Nikolskaya, T., Nikolsky, Y., Busam, D. A., Tekleab, H., Diaz, L. A., Hartigan, J., Smith, D. R., Strausberg, R. L., Marie, S. K. N., Shinjo, S. M. O., Yan, H., Riggins, G. J., Bigner, D. D., Karchin, R., Papadopoulos, N., Parmigiani, G., Vogelstein, B., Velculescu, V. E., & Kinzler, K. W.
- Affiliations
- Howard Hughes Medical Institute (US)
- Ludwig Center for Cancer Genetics and Therapeutics, and Howard Hughes Medical Institute at Johns Hopkins Kimmel Cancer Center, Baltimore, MD 21231, USA.
- Corresponding author
- Parsons, D. Williams
- Zhang, Xiaosong
- Lin, Jimmy Cheng-Ho
- Leary, Rebecca J.
- Angenendt, Philipp
- Vogelstein, Bert
- Velculescu, Victor E.
- Kinzler, Kenneth W.
- ORCID
- Parsons, D. Williams
- Zhang, Xiaosong
- Lin, Jimmy Cheng-Ho
- Leary, Rebecca J.
- Carter, Hannah
- Gallia, Gary L.
- Olivi, Alessandro
- McLendon, Roger
- Keir, Stephen
- Diaz, Luis A.
- Marie, Suely Kazue Nagahashi
- Yan, Hai
- Riggins, Gregory J.
- Bigner, Darell D.
- Karchin, Rachel
- Parmigiani, Giovanni
- Vogelstein, Bert
- Velculescu, Victor E.
- Kinzler, Kenneth W.
- Venue
- Science
- Published
- 2008-09-26
- Volume
- 321
- Issue
- 5897
- Pages
- 1807-1812
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC2820389
- OpenAlex
- W2040827479
- Cited by
- 5,857
- References
- 51
- Citations by year
- 2026: 131 · 2025: 160 · 2024: 189 · 2023: 260 · 2022: 256 · 2021: 370 · 2020: 344 · 2019: 313 · 2018: 329 · 2017: 347 · 2016: 353 · 2015: 373 · 2014: 410 · 2013: 428 · 2012: 457
- FWCI
- 172.43
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Scientific Electronic Library Online (São Paulo Research Foundation, Latin American and Caribbean Center on Health Sciences Information, Conselho Nacional de Desenvolvimento Científico e Tecnológico) (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Howard Hughes Medical Institute
- National Institutes of Health (5r01ca121113-15, 5p50ns020023-30)
- National Cancer Institute (CA108786., CA 57345, R01-CA121113, CA-121113, CA43460, CA-11898, R37CA043460, CA09547, P50CA108786, R01CA140316, P50CA062924, R37CA057345, T32CA009547, CA 62924)
- National Institute of Neurological Disorders and Stroke (5P50NS20023, R01NS052507, NS052507)
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- glioblastoma, IDH1 mutation, IDH1, somatic mutations, gene amplification, gene deletion, gene expression profiling, secondary glioblastoma, overall survival, targeted therapy
- MeSH terms
- Adult, Brain Neoplasms, Female, Gene Amplification, Glioblastoma, Humans, Isocitrate Dehydrogenase, Male, Middle Aged, Mutation, Signal Transduction, Genome, Human, Gene Expression Regulation, Neoplastic, Survival Rate, Sequence Analysis, DNA, Gene Dosage, Mutation, Missense, Oligonucleotide Array Sequence Analysis, Polymorphism, Single Nucleotide, Gene Expression Profiling
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
